Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 6
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Video Player is loading.
Video content above is prompted by the following:
- Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Recent Videos
Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
Snowmass Retina & Eye 2025: Ronald Frenkel, MD, previews the unique agenda with a fusion of retina, cataract, and glaucoma
Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
Perspectives on the Usefulness of Real-world Data
Safety Profile of New Therapies
Outcomes with Faricimab and Choosing Between the New Therapies
Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Faricimab Molecular Design and Role of Ang-2
Adverse Events of the Port Delivery System and Addressing Challenges with Adoption
Related Content
